Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Xiyuan Hospital of China Academy of Chinese Medical Sciences | OTHER |
| Dongzhimen Hospital, Beijing | OTHER |
| Beijing Chest Hospital, Capital Medical University | OTHER |
Not provided
Not provided
Not provided
Not provided
The study aims to investigate the potential mechanisms by which the interaction between the microbiota and tumors leads to the occurrence and development of cancer by collecting clinical information and biological samples from healthy individuals and cancer patients.
Study Design Types: A prospective, multicenter, observational study.
Observation Content:1.Healthy Individuals:General Information (Demographic Data), Traditional Chinese Medicine Physical Quality Scale, Biological Samples (Fecal, Blood, Tongue Coating, Tongue Appearance Photos, Tissues). 2.Malignant Tumor Patients: General Information (Demographic Data, Disease Information, ECOG Performance Status Score, MDASI Anderson Symptom Inventory), Traditional Chinese Medicine Cancer Toxin Syndrome Scale, Traditional Chinese Medicine Physical Quality Scale, Laboratory and Examination Data, Biological Samples (Fecal, Blood, Tongue Coating, Tongue Appearance Photos, Tissues).
Observation Time Points:1.Healthy Individuals: At the time of enrollment. 2.Malignant Tumor Patients: At the time of enrollment, 1 month after enrollment, every 3 months thereafter until tumor progression.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| healthy individuals and cancer patients | Comparing the microbiota characteristics of healthy individuals and cancer patients, revealing the differences in microbiota between healthy individuals and cancer patients. |
| |
| Patients with different traditional Chinese medicine cancer toxicity syndrome types | According to the classification of traditional Chinese medicine cancer toxin syndrome types, compare the differences in microbiota between the heat toxin syndrome group, dampness toxin syndrome group, stasis toxin syndrome group, phlegm toxin syndrome group, wind toxin syndrome group, and cold toxin syndrome group in cancer patients, and explore the influence of different cancer toxin syndrome types on microbiota composition. |
| |
| Patients with different traditional Chinese medicine constitutions | According to the traditional Chinese medicine constitution classification, compare the differences in microbiota among tumor patients with qi stagnation constitution group, phlegm dampness constitution group, damp heat constitution group, blood stasis constitution group, qi deficiency constitution group, yang deficiency constitution group, yin deficiency constitution group, characteristic constitution group, and peaceful constitution group, and explore the influence of different constitution types on the microbiota composition of tumor patients. |
| |
| Patients with different tumor burden | Divide tumor patients into tumor bearing group and tumor free group, and explore their microbiota characteristics and differential patterns. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention was carried out | Other | This study observed differences in microbiota among different groups and therefore did not involve intervention. |
|
| Measure | Description | Time Frame |
|---|---|---|
| 16S rDNA | 16S rDNA detection is a commonly used method in microbial molecular biology for identification and classification of bacteria. It can identify and classify bacteria. | 2 years (from enrollment to disease progression). |
| Measure | Description | Time Frame |
|---|---|---|
| microbiota metagenomics | Metagenomic Sequencing is a technique that studies the total genetic material of all microorganisms in environmental samples. This method does not rely on traditional microbial isolation and cultivation, but instead directly extracts total DNA from environmental samples to obtain new functional genes and bioactive substances by constructing and screening metagenomic libraries. |
Not provided
Inclusion Criteria:
Inclusion criteria for healthy individuals:
Inclusion criteria for patients with malignant tumors:
Exclusion Criteria:
Exclusion criteria for healthy individuals:
Exclusion criteria for patients with malignant tumors:
Not provided
Not provided
Not provided
Not provided
Healthy individuals and cancer patients.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yi Xie, PhD | Contact | 18810537596 | 18810537596@163.com | |
| Ying Zhang, PhD | Contact | 13311027150 | zylzy501@163.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
| Shanghai University of Traditional Chinese Medicine |
| OTHER |
| Shaanxi Hospital of Traditional Chinese Medicine | OTHER |
| Leling Traditional Chinese Medicine Hospital | UNKNOWN |
| Henan Medical University | OTHER |
Not provided
Not provided
Not provided
Blood, feces, tissue, tongue coating
|
| Patients with different symptom burdens | According to the MDASI Anderson Symptom Scale, compare the differences in microbiota between individuals with mild and severe symptom burdens, and explore the impact of different symptom burdens on the microbiota composition of cancer patients. |
|
| Patients with different treatment and outcome outcomes | Based on the application of different treatment methods and the resulting outcomes in cancer patients, compare the characteristic differences of microbiota between groups and explore the differential expression of microbiota. |
|
| 2 years (from enrollment to disease progression). |
| Untargeted metabolomics | Untargeted Metabolomics is a research method that does not rely on prior knowledge of specific metabolites. Instead, it explores the overall patterns and changes of metabolites by analyzing all detectable metabolites in biological samples. | 2 years (from enrollment to disease progression). |